[{"id":"55fc9994-8b85-42e1-a322-c1481d787dea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03602079","created_at":"2021-01-17T17:58:25.852Z","updated_at":"2024-07-02T16:35:41.099Z","phase":"Phase 1/2","brief_title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","source_id_and_acronym":"NCT03602079","lead_sponsor":"Klus Pharma Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sertaly (trastuzumab botidotin)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 01/12/2022","primary_completion_date":" 01/12/2022","study_txt":" Completion: 01/12/2022","study_completion_date":" 01/12/2022","last_update_posted":"2023-08-03"},{"id":"2cf0812b-3dcb-4d8b-85d9-73814b82916f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05311397","created_at":"2022-04-05T14:52:57.043Z","updated_at":"2024-07-02T16:36:12.741Z","phase":"Phase 1","brief_title":"A Study of A166 in Patients With Advanced Solid Malignant Tumors","source_id_and_acronym":"NCT05311397","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sertaly (trastuzumab botidotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/09/2018","start_date":" 08/09/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-04-14"}]